Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: Initial experience

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 5, 2010, Pages 896-903

  Verburg, Frederik A ^a   Hänscheid, Heribert ^a   Biko, Johannes ^a   Hategan, Maria C ^a   Lassmann, Michael ^a   Kreissl, Michael C ^a   Reiners, Christoph ^a   Luster, Markus ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

131I therapy; Differentiated thyroid cancer; Dosimetry; EANM standard operating procedure; Metastases

Indexed keywords

IODINE 131; ONDANSETRON; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NAUSEA; RADIOACTIVITY; RETROSPECTIVE STUDY; SIALOADENITIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; CELL DIFFERENTIATION; COHORT STUDIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; RADIATION DOSAGE; RADIOMETRY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SIALADENITIS; SURVIVAL ANALYSIS; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 77952090419     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1303-x     Document Type: Article

References (14)

1. M Luster SE Clarke M Dietlein M Lassmann P Lind WJ Oyen, et al. 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 35 1941 1959 10.1007/s00259-008-0883-1 1:STN:280: DC%2BD1cnhvVaqtQ%3D%3D 18670773
2. RM Tuttle R Leboeuf RJ Robbins R Qualey K Pentlow SM Larson, et al. 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer J Nucl Med 47 1587 1591 17015892 (Pubitemid 47545022)
3. D Van Nostrand F Atkins F Yeganeh E Acio R Bursaw L Wartofsky 2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma Thyroid 12 121 134 10.1089/105072502753522356 11916281 (Pubitemid 34218137)
4. RS Benua NR Cicale M Sonenberg RW Rawson 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer Am J Roentgenol Radium Ther Nucl Med 87 171 182 1:STN:280: DyaF38%2FgvVKktg%3D%3D 13867399
5. Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan G, editors. Frontiers in thyroidology. New York: Plenum Medical Book Co; 1986. p. 1317-21.
6. M Lassmann H Hänscheid C Chiesa C Hindorf G Flux M Luster, et al. 2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy Eur J Nucl Med Mol Imaging 35 1405 1412 10.1007/s00259-008-0761-x 18491092
7. H Hänscheid M Lassmann M Luster SR Thomas F Pacini C Ceccarelli, et al. 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal J Nucl Med 47 648 654 16595499 (Pubitemid 46768466)
8. M Lassmann M Luster H Hänscheid C Reiners 2004 Impact of 131I diagnostic activities on the biokinetics of thyroid remnants J Nucl Med 45 619 625 15073258 (Pubitemid 47618592)
9. Common terminology criteria for adverse events v3.0 (CTCAE). Rockville, MD: National Cancer Institute, 2006.
10. R Dorn J Kopp H Vogt P Heidenreich RG Carroll SA Gulec 2003 Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach J Nucl Med 44 451 456 1:CAS:528:DC%2BD3sXislKnur4%3D 12621014 (Pubitemid 39586024)
11. JJ Lee JK Chung SE Kim WJ Kang DJ Park DS Lee, et al. 2008 Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma Ann Nucl Med 22 727 734 10.1007/s12149-007- 0179-8 19039550
12. FA Verburg R Verkooijen M Stokkel J van Isselt 2009 The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I Nuklearmedizin 48 138 142 1:STN:280: DC%2BD1MrjtVGltQ%3D%3D 19384451
13. M Medvedec 2005 Thyroid stunning in vivo and in vitro Nucl Med Commun 26 731 735 10.1097/01.mnm.0000169380.92270.73 16000993 (Pubitemid 41073376)
14. C Alexander JB Bader A Schaefer C Finke CM Kirsch 1998 Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma J Nucl Med 39 1551 1554 1:CAS:528:DyaK1cXmtlyhsr0%3D 9744341 (Pubitemid 28459885)